Reading the tape
NYSE: MED
Medifast, Inc.
Consumer Cyclical · Personal Products & Services
Market Cap
$117.27M
52w High
$15.46
52w Low
$9.22
P/E
-5.84
Volume
150.46K
Outstanding Shares
11.03M
Price vs Fundamentals
Why The Stock Is Moving
Likely fundamental deteriorationHigh confidence
1Y Price: -18.85%Revenue (TTM): -36.31%FCF (TTM): -110.92%P/FCF: 97th pct
What changed
The stock fell 18.85% over the last year. Revenue declined 36.31% over the trailing twelve months. Operating margin moved from -1.16% to -4.69%. Free cash flow declined 110.92% over the trailing twelve months.
What the market seems to be pricing
The market is reacting to weaker business momentum more than just compressing the valuation multiple. Even if the shares already screen cheap on P/FCF, investors are still discounting lower future earnings power.
What would invalidate this read
Operating margin stands at -4.69%. Revenue declined 36.31% — this read reverses if that trend stabilizes. Free cash flow fell 110.92% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific.
CEODaniel R. Chard
SectorConsumer Cyclical
IndustryPersonal Products & Services
Employees504
IPO dateDec 30, 1993
Valuation
Forward P/E—
EV/EBITDA-12.05
Enterprise value$44.76M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth-34.29%
Gross margin70.12%▼3.35%vs FY2024
Operating margin-4.69%▼871.22%vs FY2024
ROE-9.39%▼1043.20%vs FY2024
Analyst consensus
RatingHold
Target price$12.00▲12.89%
4
Buy
6
Hold
2
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 3, 2026
Q3 FY26 · EPS est -$0.42 · Revenue est $74.7M
View